drug
Simponi Aria
Marketedupdated 6mo agoby Janssen Biotech Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3all catalysts(0)
nothing on the calendar yet
Trials studying Simponi Aria
- phase3Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
- phase2A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
- phase2A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
- phase2Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
- phase3A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
- phase2A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis
- phase3GOLimumab and Methotrexate Versus Methotrexate in Very Early PsA
- phase3A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that